{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:59:30Z","timestamp":1791280770345,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T00:00:00Z","timestamp":1574294400000},"content-version":"vor","delay-in-days":2637,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Cancer and Leukemia Group B (CALGB); Biogen Idec to MSC"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1093\/annonc\/mdr620","type":"journal-article","created":{"date-parts":[[2012,2,23]],"date-time":"2012-02-23T02:05:39Z","timestamp":1329962739000},"page":"2356-2362","source":"Crossref","is-referenced-by-count":60,"title":["Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness"],"prefix":"10.1016","volume":"23","author":[{"given":"M.S.","family":"Czuczman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.P.","family":"Leonard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.L.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.D.","family":"Hsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.C.","family":"Byrd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.D.","family":"Cheson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdr620_bb0010","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1182\/blood.V85.12.3671.bloodjournal85123671","article-title":"Prognostic value of cellular proliferation and histologic grade in follicular lymphoma","volume":"85","author":"Martin","year":"1995","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdr620_bb0015","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1200\/JCO.2009.26.1693","article-title":"Prognostic factors in follicular lymphoma","volume":"28","author":"Relander","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr620_bb0020","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-Celigny","year":"2004","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdr620_bb0025","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.1999.17.1.268","article-title":"Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy","volume":"17","author":"Czuczman","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr620_bb0030","doi-asserted-by":"crossref","first-page":"4390","DOI":"10.1200\/JCO.2005.09.018","article-title":"Phase I\/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma","volume":"23","author":"Czuczman","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr620_bb0035","doi-asserted-by":"crossref","first-page":"4711","DOI":"10.1200\/JCO.2004.04.020","article-title":"Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up","volume":"22","author":"Czuczman","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr620_bb0040","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdr620_bb0045","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdr620_bb0050","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3324\/haematol.11671","article-title":"High clinical and molecular response rates with fludarabine, cyclophosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphoma","volume":"93","author":"Montoto","year":"2008","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mdr620_bb0055","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1182\/blood.V114.22.405.405","volume":"114","author":"Rummel","year":"2009","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdr620_bb0060","doi-asserted-by":"crossref","first-page":"5156","DOI":"10.1200\/JCO.2008.17.2015","article-title":"Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma","volume":"26","author":"Morschhauser","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr620_bb0065","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1182\/blood.V97.1.101","article-title":"Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation","volume":"97","author":"Colombat","year":"2001","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdr620_bb0070","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1053\/sonc.2003.50023","article-title":"First-line and maintenance treatment with rituximab for patients with indolent non-Hodgkin's lymphoma","volume":"30","author":"Hainsworth","year":"2003","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdr620_bb0075","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1182\/blood.V95.10.3052","article-title":"Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma","volume":"95","author":"Hainsworth","year":"2000","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdr620_bb0080","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1200\/JCO.2005.12.052","article-title":"Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group","volume":"23","author":"Witzig","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr620_bb0085","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","article-title":"Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule","volume":"103","author":"Ghielmini","year":"2004","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdr620_bb0090","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1200\/JCO.2010.28.4786","article-title":"Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35\/98","volume":"28","author":"Martinelli","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr620_bb0095","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1002\/cncr.25434","article-title":"Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence","volume":"116","author":"Faderl","year":"2010","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdr620_bb0100","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1002\/cncr.23890","article-title":"Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma","volume":"113","author":"Leonard","year":"2008","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdr620_bb0105","doi-asserted-by":"crossref","first-page":"4556","DOI":"10.1158\/1078-0432.CCR-07-0680","article-title":"Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20","volume":"13","author":"Maddipatla","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdr620_bb0110","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/85251","article-title":"The expanding B7 superfamily: increasing complexity in costimulatory signals regulating T cell function","volume":"2","author":"Coyle","year":"2001","journal-title":"Nat Immunol"},{"key":"10.1093\/annonc\/mdr620_bb0115","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0955-0674(99)80027-1","article-title":"Costimulatory regulation of T cell function","volume":"11","author":"Chambers","year":"1999","journal-title":"Curr Opin Cell Biol"},{"key":"10.1093\/annonc\/mdr620_bb0120","doi-asserted-by":"crossref","first-page":"7766","DOI":"10.1074\/jbc.M105902200","article-title":"Distinct role of CD80 and CD86 in the regulation of the activation of B cell and B cell lymphoma","volume":"277","author":"Suvas","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1093\/annonc\/mdr620_bb0125","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1182\/blood.V83.3.793.793","article-title":"In vivo expression of the B7 costimulatory molecule by subsets of antigen-presenting cells and the malignant cells of Hodgkin's disease","volume":"83","author":"Munro","year":"1994","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdr620_bb0130","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1517\/14712591003596318","article-title":"Galiximab: a review","volume":"10","author":"Bhat","year":"2010","journal-title":"Expert Opin Biol Ther"},{"key":"10.1093\/annonc\/mdr620_bb0135","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3816\/CLM.2008.n.038","article-title":"The use of galiximab in non-Hodgkin lymphoma","volume":"8","author":"Vinjamaram","year":"2008","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1093\/annonc\/mdr620_bb0140","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1093\/annonc\/mdm114","article-title":"A phase I\/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma","volume":"18","author":"Leonard","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdr620_bb0145","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr620_bb0150","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood.V99.3.754","article-title":"Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene","volume":"99","author":"Cartron","year":"2002","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdr620_bb0155","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1200\/JCO.2003.05.013","article-title":"Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma","volume":"21","author":"Weng","year":"2003","journal-title":"J Clin Oncol"},{"issue":"Suppl 5","key":"10.1093\/annonc\/mdr620_bb0160","doi-asserted-by":"crossref","first-page":"v181","DOI":"10.1093\/annonc\/mdq184","article-title":"Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"21","author":"Dreyling","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdr620_bb0165","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1080\/10428190802713513","article-title":"First-line treatment of follicular lymphoma: a patient-oriented algorithm","volume":"50","author":"Feuerlein","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1093\/annonc\/mdr620_bb0170","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1200\/JCO.2008.18.1495","article-title":"Follicular lymphoma in the United States: first report of the national LymphoCare study","volume":"27","author":"Friedberg","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr620_bb0175","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/cncr.24714","article-title":"Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study","volume":"116","author":"Kahl","year":"2010","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdr620_bb0180","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/nrclinonc.2009.159","article-title":"Hematology: Follicular lymphoma: maintenance therapy is (often) indicated","volume":"6","author":"Seymour","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1093\/annonc\/mdr620_bb0185","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1182\/blood-2008-11-188896","article-title":"A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody\/radioantibody therapy","volume":"113","author":"Sharkey","year":"2009","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdr620_bb0190","doi-asserted-by":"crossref","first-page":"5404","DOI":"10.1200\/JCO.2008.21.1169","article-title":"Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma","volume":"27","author":"Witzig","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr620_bb0195","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdr620_bb0200","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/blood-2006-01-013367","volume":"108","author":"Buske","year":"2006","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdr620_bb0205","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/annonc\/mdl162","article-title":"The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma","volume":"17","author":"Gine","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdr620_bb0210","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1093\/annonc\/mdh406","article-title":"Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progression","volume":"15","author":"Montoto","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdr620_bb0215","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood.V116.21.6.6","article-title":"An intergroup randomized trial of rituximab versus a watch and wait strategy in patients with stage II, III, IV, asymptomatic, non-bulky follicular lymphoma (Grades 1, 2, and 3a). A preliminary analysis","volume":"116","author":"Ardeshna","year":"2010","journal-title":"Blood"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419351919?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419351919?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/23\/9\/2356\/23872137\/mdr620.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,20]],"date-time":"2024-04-20T04:02:01Z","timestamp":1713585721000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419351919"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":42,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S0923753419351919"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdr620","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}